GH RESEARCH PLC

GH Research shares rose 16.4% premarket to $31.34 after reports that Eli Lilly is in advanced takeover talks with AtaiBeckley, sparking speculation of further M&A activity in the psychedelics sector. An RBC analyst viewed GH Research as the main beneficiary of the news and reiterated expectations of targeted interest from large pharma firms in the pipeline, fueling institutional buying. Recent positive signals from the FDA and a government regulation to accelerate the development of psychedelic therapies also provided support. » More on de.investing.com

GH Research PLC has entered into an agreement with Stifel for an at-the-market offering pursuant to which the company may sell common shares from time to time with an aggregate value of up to US$200 million. The sales will be made pursuant to Rule 415(a)(4) of the Securities Act and are covered by a previously filed registration statement on Form F-3. A prospectus supplement and related documents have been filed with the SEC and are available as exhibits to Form 6-K. » More on de.investing.com

GH Research has informed its shareholders of an annual general meeting to be held on June 25, 2026 at 13:30 Irish time at Joshua Dawson House in Dublin. The company is making the agenda, proxy materials and voting cards available for registered shareholders and brokers. At the same time, the directors’ report and the 2025 financial statements prepared under Irish law have been published; the information is provided based on a recent SEC filing. » More on de.investing.com

GH Research has placed a guaranteed public offering of 6,527,779 common shares at $18.00 per share and expects gross proceeds of approximately $117.5 million before fees. The closing of the transaction is expected on Thursday, subject to customary conditions. The placement was initiated by Lynx1 Capital Management, with participants including Deep Track Capital and Foresite Capital; Stifel, Cantor and RBC Capital Markets are leading the syndicate. » More on de.investing.com

GH Research reports in JAMA Psychiatry full phase‑2b results for GH001 (Mebufotenin) that showed a significant reduction in MADRS scores at day 8 versus placebo (−15.5 points; p < 0.0001). An additional analysis in Psychopharmacology Bulletin shows high remission rates at day 8 and at six months regardless of the number of prior unsuccessful antidepressant treatments. The stock recently fell 11% despite the data; analyst targets still range from $25 to $70. » More on de.investing.com